EP Patent

EP3891169A1 — An improved process for the preparation of plecanatide

Assigned to Enzene Biosciences Ltd · Expires 2021-10-13 · 5y expired

What this patent protects

The present invention generally relates to a process for the preparation of plecanatide. Specifically, the present invention relates to an improved process for preparation of plecanatide using a non-linear solid phase peptide synthesis. In particular, the process for preparation …

USPTO Abstract

The present invention generally relates to a process for the preparation of plecanatide. Specifically, the present invention relates to an improved process for preparation of plecanatide using a non-linear solid phase peptide synthesis. In particular, the process for preparation of plecanatide of the present invention involves solid phase synthesis of peptide fragments of five amino acid units using 2-chlorotrityl chloride (2-ClTrt) resin and eleven amino acid unit using Wang resin.

Drugs covered by this patent

Patent Metadata

Patent number
EP3891169A1
Jurisdiction
EP
Classification
Expires
2021-10-13
Drug substance claim
No
Drug product claim
No
Assignee
Enzene Biosciences Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.